相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
Jose Manuel Perez-Garcia et al.
NEURO-ONCOLOGY (2023)
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
Min Yan et al.
LANCET ONCOLOGY (2022)
Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer
Alex Cordero et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients
Wuguo Tian et al.
ANTI-CANCER DRUGS (2022)
Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
R. Bartsch et al.
ANNALS OF ONCOLOGY (2022)
The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis
Cedric Tehranian et al.
NEURO-ONCOLOGY (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
Pasi A. Janne et al.
CANCER DISCOVERY (2022)
Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
Erika P. Hamilton et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
NEO100 enables brain delivery of blood-brain barrier impermeable therapeutics
Weijun Wang et al.
NEURO-ONCOLOGY (2021)
HER3 Is an Actionable Target in Advanced Prostate Cancer
Veronica Gil et al.
CANCER RESEARCH (2021)
FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important of the HER-2/ErbB2 Oncogene
Tao Zuo et al.
CELL (2021)
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Daniela Miricescu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Blood-Brain Barrier Dynamics to Maintain Brain Homeostasis
Marta Segarra et al.
TRENDS IN NEUROSCIENCES (2021)
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Binghe Xu et al.
NATURE MEDICINE (2021)
The Pharmacology of Xenobiotics after Intracerebro Spinal Fluid Administration: Implications for the Treatment of Brain Tumors
Justine Paris et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Strategies for delivering therapeutics across the blood-brain barrier
Georg C. Terstappen et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer
Weijun Wang et al.
NEURO-ONCOLOGY (2021)
HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
Kimio Yonesaka
CANCERS (2021)
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Biology and Models of the Blood-Brain Barrier
Cynthia Hajal et al.
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 23, 2021 (2021)
Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
Guy Heinrich Maria Jerusalem et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
Sara A. Hurvitz et al.
ONCOLOGIST (2021)
Long noncoding RNAs in cancer metastasis
S. John Liu et al.
NATURE REVIEWS CANCER (2021)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers
Yun Song et al.
CANCER (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
How to Make Anticancer Drugs Cross the Blood-Brain Barrier to Treat Brain Metastases
Eurydice Angeli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J. Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
F. Montemurro et al.
ANNALS OF ONCOLOGY (2020)
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
The genomic landscape of breast cancer brain metastases: a systematic review
Alexander J Morgan et al.
LANCET ONCOLOGY (2020)
The blood-brain barrier and blood-tumour barrier in brain tumours and metastases
Costas D. Arvanitis et al.
NATURE REVIEWS CANCER (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
Development and Cell Biology of the Blood-Brain Barrier
Urs H. Langen et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 35 (2019)
Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
Franziska Maria Ippen et al.
NEURO-ONCOLOGY (2019)
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Shigehiro Koganemaru et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
Amelie Darlix et al.
BRITISH JOURNAL OF CANCER (2019)
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases
Amanda E. D. Van Swearingen et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia
Raquel Blazquez et al.
GLIA (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies
Evelyn M. Brosnan et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
NOTCH3 expression is linked to breast cancer seeding and distant metastasis
Alexey A. Leontovich et al.
BREAST CANCER RESEARCH (2018)
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)
Sara Hurvitz et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Nandini Dey et al.
PHARMACOLOGY & THERAPEUTICS (2017)
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
David P. Kodack et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Jennifer L. Hsu et al.
CANCER AND METASTASIS REVIEWS (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
MRI Virtual Biopsy and Treatment of Brain Metastatic Tumors with Targeted Nanobioconjugates: Nanoclinic in the Brain
Rameshwar Patil et al.
ACS NANO (2015)
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study
Minesh P. Mehta et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
Jodi M. Saunus et al.
JOURNAL OF PATHOLOGY (2015)
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth
Lin Zhang et al.
NATURE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling
Laura Braccini et al.
NATURE COMMUNICATIONS (2015)
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda et al.
NATURE COMMUNICATIONS (2015)
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla K. Brastianos et al.
CANCER DISCOVERY (2015)
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
I. E. Krop et al.
ANNALS OF ONCOLOGY (2015)
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study
Aki Morikawa et al.
NEURO-ONCOLOGY (2015)
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Thomas J. Raub et al.
DRUG METABOLISM AND DISPOSITION (2015)
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
S. M. Swain et al.
ANNALS OF ONCOLOGY (2014)
Metastatic breast cancer subtypes and central nervous system metastases
C. Aversa et al.
BREAST (2014)
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis
Naoki Niikura et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Applications of Nanoparticles for Brain Cancer Imaging and Therapy
Liang Zhang et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context
Fabienne Schmit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Frequent Genetic Alterations in EGFR- and HER2-Driven Pathways in Breast Cancer Brain Metastases
Ina Hohensee et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
E. M. Olson et al.
ANNALS OF ONCOLOGY (2013)
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
Erin M. Olson et al.
BREAST (2013)
Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain
Fei Xing et al.
EMBO MOLECULAR MEDICINE (2013)
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot et al.
LANCET ONCOLOGY (2013)
Regulatory networks defining EMT during cancer initiation and progression
Bram De Craene et al.
NATURE REVIEWS CANCER (2013)
EFFECT OF TUMOR SUBTYPE ON SURVIVAL AND THE GRADED PROGNOSTIC ASSESSMENT FOR PATIENTS WITH BREAST CANCER AND BRAIN METASTASES
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Relevance of PTEN loss in brain metastasis formation in breast cancer patients
Harriet Wikman et al.
BREAST CANCER RESEARCH (2012)
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
G. Metro et al.
ANNALS OF ONCOLOGY (2011)
β-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis
F. Klemm et al.
CARCINOGENESIS (2011)
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
Adam M. Brufsky et al.
CLINICAL CANCER RESEARCH (2011)
The biology of brain metastases-translation to new therapies
April F. Eichler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
Barbara Adamo et al.
BREAST CANCER RESEARCH (2011)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
Defining prognosis for women with breast cancer and CNS metastases by HER2 status
S. Dawood et al.
ANNALS OF ONCOLOGY (2008)
Subtypes of breast cancer show preferential site of relapse
Marcel Smid et al.
CANCER RESEARCH (2008)
Activation of Notch signaling in a xenograft model of brain metastasis
Do-Hyun Nam et al.
CLINICAL CANCER RESEARCH (2008)
A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Targeting the function of the HER2 oncogene in human cancer therapeutics
M. M. Moasser
ONCOGENE (2007)
Central nervous system metastases in HER-2-positive metastatic breast cancer patients treated with trastuzumab:: Incidence, survival, and risk factors
Stefania Gori et al.
ONCOLOGIST (2007)
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain
Diane Palmieri et al.
CANCER RESEARCH (2007)
Spectrum of breast cancer metastasis in BRCA1 mutation carriers:: highly increased incidence of brain metastases
L Albiges et al.
ANNALS OF ONCOLOGY (2005)
EGFR gene amplification in breast cancer:: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations
R Bhargava et al.
MODERN PATHOLOGY (2005)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cancer susceptibility and the functions of BRCA1 and BRCA2
AR Venkitaraman
CELL (2002)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
